Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Lorusso, Domenica *, Xiang, Yang, Hasegawa, Kosei, Scambia, Giovanni, Leiva, Manuel, Ramos-Elias, Pier, Acevedo, Alejandro, Cvek, Jakub, Randall, Leslie, Pereira de Santana Gomes, Andrea Juliana, Contreras Mejía, Fernando, Helpman, Limor, Akıllı, Hüseyin, Lee, Jung-Yun, Saevets, Valeriya, Zagouri, Flora, Gilbert, Lucy, Sehouli, Jalid, Tharavichitkul, Ekkasit, Lindemann, Kristina, Colombo, Nicoletta, Chang, Chih-Long, Bednarikova, Marketa, Zhu, Hong, Oaknin, Ana, Christiaens, Melissa, Petru, Edgar, Usami, Tomoka, Liu, Peng, Yamada, Karin, Toker, Sarper, Keefe, Stephen M, Pignata, Sandro *, Duska, Linda R *
Zdroj: In The Lancet 5-11 October 2024 404(10460):1321-1332
Databáze: ScienceDirect